News & Events about Ocular Therapeutix Inc.
Dextenza Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2022 is Estimated to be $50.2 million, Representing ...
Business Wire
2 months ago
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Jefferies London Healthcare...
Ocular Therapeutix, Inc. (NASDAQ:OCUL Get Rating) major shareholder Summer Road Llc purchased 10,000 shares of the businesss stock in a transaction dated Monday, October 10th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the ...
Ticker Report
3 months ago
StockNews.com upgraded shares of Ocular Therapeutix (NASDAQ:OCUL Get Rating) from a sell rating to a hold rating in a report published on Saturday. Separately, JMP Securities lifted their price objective on shares of Ocular Therapeutix from $20.00 to $25.00 and gave the company a market ...